21:52 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends label update to AZ's Bydureon

EMA's CHMP recommended expanding the label of Bydureon exenatide from AstraZeneca plc (LSE:AZN; NYSE:AZN) to include treatment of Type II diabetes in combination with other glucose lowering treatments, including basal insulin, when use of Bydureon...
23:09 , Aug 16, 2017 |  BC Week In Review  |  Clinical News

AZ's Bydureon improves motor function in Phase II for PD

Data published in The Lancet showed that diabetes drug Bydureon exenatide from AstraZeneca plc (LSE:AZN; NYSE:AZN) met the primary endpoint in the Phase II EXENATIDE-PD trial to treat moderate Parkinson’s disease. In the 60-patient trial,...
22:01 , Jun 21, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Polymers PEG-based hydrogel microspheres that release peptide drugs continuously over several weeks could help treat Type II diabetes and other chronic diseases with once-monthly dosing. The microspheres are linked to peptide therapeutics via a carbamate...
17:15 , Jun 2, 2017 |  BC Week In Review  |  Company News

AZ and Harvard Pilgrim sign two outcomes-based drug pricing contracts

Regional insurer Harvard Pilgrim Health Care Inc. (Boston, Mass.) signed two outcomes-based drug pricing contracts with AstraZeneca plc (LSE:AZN; NYSE:AZN). The insurer signed a three-year contract for AZ’s Brilinta ticagrelor, which is marketed in the U.S....
20:06 , May 19, 2017 |  BC Week In Review  |  Company News

3SBio acquires China rights to Lilly's Humulin

Eli Lilly and Co. (NYSE:LLY) granted 3SBio Inc. (HKSE:1530) exclusive rights to distribute and promote its diabetes drug Humulin in China, beginning July 1. Lilly's China unit will be responsible for manufacturing the drug, while 3SBio...
17:14 , May 19, 2017 |  BioCentury  |  Strategy

Contracting 2.0

Pricing doesn’t always cause business discontinuities -- but it’s always the double-edged sword at the center of the action, helping innovators and hobbling laggards. Discount brokers revolutionized consumer investing; discounted long-distance ultimately destroyed AT&T. Price...
18:49 , May 17, 2017 |  BC Extra  |  Company News

3SBio acquires China rights to Lilly's Humulin

Eli Lilly and Co. (NYSE:LLY) granted 3SBio Inc. (HKSE:1530) exclusive rights to distribute and promote its diabetes drug Humulin in China, beginning July 1. Lilly's China unit will be responsible for manufacturing the drug, while 3SBio...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Company News

AstraZeneca, 3SBio deal

AstraZeneca granted 3SBio exclusive, Chinese rights to commercialize diabetes drugs Byetta exenatide and its once-weekly form, Bydureon. AZ will receive $50 million up front and is eligible for up to $50 million in milestones. AZ...
07:00 , Oct 11, 2016 |  BC Extra  |  Company News

3SBio gets Chinese rights to Byetta, Bydureon

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted 3SBio Inc. (HKSE:1530) an exclusive license to commercialize diabetes drugs Byetta exenatide and its once-weekly form Bydureon in China. 3SBio is paying AstraZeneca $50 million up front and up to...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

Bydureon: Phase III data

The double-blind, international Phase III DURATION-8 trial in 695 Type II diabetics inadequately controlled on metformin showed that once-weekly 2 mg subcutaneous Bydureon exenatide plus once-daily 10 mg oral Farxiga dapagliflozin met the primary...